---
layout: default
title: Oxytetracycline
description: "Oxytetracycline çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 121
evidence_level: L3
indication_count: 10
---

# Oxytetracycline

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Oxytetracycline è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Oxytetracycline å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Oxytetracycline ç‚ºå»£æ•ˆæ€§å››ç’°ç´ é¡æŠ—ç”Ÿç´ ï¼ŒTxGNN é æ¸¬å…¶å¯èƒ½å°å¤–è€³ç‚æœ‰æ²»ç™‚æ•ˆæœï¼Œæ–‡ç»é¡¯ç¤ºå¤šé …ç ”ç©¶å·²é©—è­‰å…¶åœ¨è€³éƒ¨æ„ŸæŸ“çš„ç™‚æ•ˆï¼Œè­‰æ“šç­‰ç´šä¸­ç­‰ã€‚
</p>

---

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥å“åç¨± | Oxytetracycline (ç¾¥å››ç’°ç´ ) |
| DrugBank ID | DB00595 |
| å°ç£å•†å“å | é¹½é…¸ç¾¥å››ç’°ç´ è† å›Šç­‰ |
| åŸé©æ‡‰ç—‡ | é©è˜­æ°é™½æ€§åŠé™°æ€§èŒæ„ŸæŸ“ç—‡ã€èºæ—‹èŒæ„ŸæŸ“ç—‡ã€ç«‹å…‹æ¬¡é«”æ„ŸæŸ“ç—‡ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | conjunctivitisã€chronic rhinosinusitisã€chronic ethmoidal sinusitisã€sinusitisã€paranasal sinus neoplasm (disease)ã€punctate epithelial keratoconjunctivitisã€postinfectious vasculitisã€post-bacterial disorderã€post-infectious syndromeã€infective urethral stricture |
| è­‰æ“šç­‰ç´š | L2 (å–®ä¸€ RCT / å¤šå€‹è‡¨åºŠç ”ç©¶) |
| TxGNN é æ¸¬åˆ†æ•¸ | é«˜åˆ†é æ¸¬ |

---





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. chronic rhinosinusitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.61%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>### æ©Ÿè½‰é€£çµ</p>

<ol>
<li><strong>å»£æ•ˆæŠ—èŒä½œç”¨</strong>ï¼šOxytetracycline æŠ‘åˆ¶ç´°èŒ 30S æ ¸ç³–é«”äºåŸºï¼Œå°é€ æˆå¤–è€³ç‚çš„å¸¸è¦‹ç—…åŸé«”å¦‚è‘¡è„çƒèŒã€ç¶ è†¿æ¡¿èŒç­‰æœ‰æ•ˆã€‚</li>

<li><strong>å±€éƒ¨è£½åŠ‘å¯ç”¨æ€§</strong>ï¼šå·²æœ‰å« oxytetracycline çš„è€³ç”¨è¤‡æ–¹è£½åŠ‘ä¸Šå¸‚ï¼Œå¸¸èˆ‡ polymyxin B æˆ–é¡å›ºé†‡åˆç”¨ã€‚</li>

<li><strong>å”åŒæŠ—èŒä½œç”¨</strong>ï¼šç ”ç©¶é¡¯ç¤º EDTA-Tris èˆ‡ oxytetracycline åˆç”¨å°ç¶ è†¿æ¡¿èŒæœ‰å”åŒæŠ‘åˆ¶ä½œç”¨ã€‚</li>
</ol>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>ç›®å‰ç„¡é‡å°æ­¤ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. chronic ethmoidal sinusitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.61%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. paranasal sinus neoplasm (disease)</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.58%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. punctate epithelial keratoconjunctivitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.52%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. postinfectious vasculitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.37%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. post-bacterial disorder</span>
<span class="evidence-badge evidence-L3">L3</span>
<span class="prediction-score">99.35%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ1 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02099240" target="_blank">NCT02099240</a></td><td>EARLY_PHASE1</td><td>TERMINATED</td><td>11</td><td>Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteo...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. post-infectious syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.33%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. infective urethral stricture</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.28%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. Chagas cardiomyopathy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.27%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. otitis externa</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.27%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8222746/" target="_blank">8222746</a></td><td>1993</td><td>Article</td><td>Current medical research and o</td><td>Otitis externa: clinical comparison of local ciprofloxacin versus local oxytetra...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14412537/" target="_blank">14412537</a></td><td>1959</td><td>Article</td><td>Monatsschrift fur Ohrenheilkun</td><td>[Treatment of otitis externa with oxytetracycline and hydrocortisone].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12564664/" target="_blank">12564664</a></td><td>2002</td><td>Article</td><td>Current medical research and o</td><td>Comparative efficacy of two anti-bacterial/anti-inflammatory formulations (Auric...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6451857/" target="_blank">6451857</a></td><td>1980</td><td>Article</td><td>Otolaryngology and head and ne</td><td>Drug therapy of aspergillus otitis externa.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/5423936/" target="_blank">5423936</a></td><td>1970</td><td>Article</td><td>The Indian veterinary journal</td><td>Canine otitis externa: aetiological factors and a comparison of the therapeutic ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2415098/" target="_blank">2415098</a></td><td>1985</td><td>Article</td><td>Archives of oto-rhino-laryngol</td><td>A randomized clinical trial of two topical preparations (framycitin/gramicidin a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/1782715/" target="_blank">1782715</a></td><td>1991</td><td>Article</td><td>Clinical otolaryngology and al</td><td>A randomized prospective comparison of two methods of administering topical trea...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40981334/" target="_blank">40981334</a></td><td>2025</td><td>Article</td><td>Infectious disease reports</td><td>Uncommon Pathogens in Common Presentations: Genetic Profiling and Virulence Dete...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2156538/" target="_blank">2156538</a></td><td>1990</td><td>Article</td><td>European archives of oto-rhino</td><td>A clinical comparison of hydrocortisone butyrate with oxytetracycline/hydrocorti...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/13447965/" target="_blank">13447965</a></td><td>1957</td><td>Article</td><td>Eye, ear, nose &amp; throat monthl</td><td>Treatment of otitis externa with terra-cortril suspension.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15949095/" target="_blank">15949095</a></td><td>2005</td><td>Article</td><td>The Journal of laryngology and</td><td>A group III steroid solution without antibiotic components: an effective cure fo...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/14170748/" target="_blank">14170748</a></td><td>1964</td><td>Article</td><td>The Journal of laryngology and</td><td>FUNGUS INFECTION OF THE EAR (CLINICAL AND CULTURAL STUDIES).</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15823803/" target="_blank">15823803</a></td><td>2005</td><td>Article</td><td>Acta oto-laryngologica</td><td>External otitis caused by infection with Pseudomonas aeruginosa or Candida albic...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11583468/" target="_blank">11583468</a></td><td>2001</td><td>Article</td><td>European archives of oto-rhino</td><td>A topical steroid without an antibiotic cures external otitis efficiently: a stu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/13313924/" target="_blank">13313924</a></td><td>1956</td><td>Article</td><td>American practitioner and dige</td><td>Treatment of infected ears with terramycin-polymyxin ear drops.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6412426/" target="_blank">6412426</a></td><td>1983</td><td>Article</td><td>Veterinary microbiology</td><td>Action of EDTA-Tris and antimicrobial agent combinations on selected pathogenic ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/13222880/" target="_blank">13222880</a></td><td>1954</td><td>Article</td><td>The Laryngoscope</td><td>An evaluation of certain therapeutic agents and procedures in the treatment of a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12019482/" target="_blank">12019482</a></td><td>2002</td><td>Article</td><td>American journal of otolaryngo</td><td>The use of otic powder in the treatment of acute external otitis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6414345/" target="_blank">6414345</a></td><td>1983</td><td>Article</td><td>American journal of veterinary</td><td>In vitro action of combinations of antimicrobial agents and EDTA-tromethamine on...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24049916/" target="_blank">24049916</a></td><td>1984</td><td>Article</td><td>American journal of veterinary</td><td>In vitro action of combinations of antimicrobial agents with EDTA-tromethamine o...</td></tr>
</tbody>
</table>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | åŠ‘å‹ | é©æ‡‰ç—‡ | ç‹€æ…‹ |
|-----------|--------|------|--------|------|
| å…§è¡›è—¥è£½å­—ç¬¬006780è™Ÿ | é¹½é…¸ç¾¥å››ç’°ç´ è† å›Š 250mg | è† å›Š | æ”¯æ°£ç®¡ç‚ã€Qç†±ã€ç´°èŒæ€§ç—¢ç–¾ã€æ‰æ¡ƒè…ºç‚ã€è»Ÿæ€§ä¸‹ç–³ã€è€³ç‚ã€èƒƒè…¸ç‚ | æœ‰æ•ˆ |

**æ³¨æ„**ï¼šåŸé©æ‡‰ç—‡å·²åŒ…å«ã€Œè€³ç‚ã€ï¼Œæ­¤é æ¸¬å¯¦éš›ä¸Šç‚ºé©æ‡‰ç—‡ç¯„åœå…§çš„æ‡‰ç”¨ã€‚

å¤§å¤šæ•¸å« oxytetracycline çš„å°ç£è—¥è­‰å·²è¨»éŠ·ï¼Œç›®å‰æœ‰æ•ˆè—¥è­‰æœ‰é™ã€‚

---

## å®‰å…¨æ€§è€ƒé‡

### é‡è¦è­¦èª

- **å…‰æ•æ„Ÿæ€§**ï¼šå››ç’°ç´ é¡å¯èƒ½å°è‡´åš´é‡å…‰æ•æ„Ÿåæ‡‰
- **ç‰™é½’åŠéª¨éª¼ç™¼è‚²å½±éŸ¿**ï¼šå­•å©¦åŠ8æ­²ä»¥ä¸‹å…’ç«¥ç¦ç”¨ï¼Œå¯èƒ½é€ æˆç‰™é½’æ°¸ä¹…è®Šè‰²åŠéª¨éª¼ç™¼è‚²éšœç¤™
- **è…¸èƒƒé“åæ‡‰**ï¼šå¸¸è¦‹å™å¿ƒã€å˜”åã€è…¹ç€‰

### è—¥ç‰©äº¤äº’ä½œç”¨

| äº¤äº’ä½œç”¨è—¥ç‰© | å½±éŸ¿èªªæ˜ |
|-------------|----------|
| åˆ¶é…¸åŠ‘ (å«é‹ã€é‚ã€éˆ£) | é™ä½ oxytetracycline å¸æ”¶ |
| å£æœæŠ—å‡è¡€åŠ‘ | å¯èƒ½å¢å¼·æŠ—å‡ä½œç”¨ |
| é’é»´ç´ é¡ | å¯èƒ½é™ä½é’é»´ç´ ç™‚æ•ˆ |
| å£æœé¿å­•è—¥ | å¯èƒ½é™ä½é¿å­•æ•ˆæœ |

### ç‰¹æ®Šæ—ç¾¤

- **å­•å©¦**ï¼šç¦å¿Œä½¿ç”¨ (Category D)
- **å“ºä¹³å©¦å¥³**ï¼šä¸å»ºè­°ä½¿ç”¨
- **8æ­²ä»¥ä¸‹å…’ç«¥**ï¼šç¦å¿Œä½¿ç”¨
- **è…åŠŸèƒ½ä¸å…¨**ï¼šéœ€èª¿æ•´åŠ‘é‡

---


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Diseases requiring hemodialysis** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šOxytetracycline is partially removed by hemodialysis...

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šè‚æ¯’æ€§ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**Esophageal Diseases** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šThe use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug with...

**Colitis** ğŸŸ¢ Minor
- é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**ä¹³è£½å“** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šå½±éŸ¿è—¥ç‰©å¸æ”¶ã€‚
- å»ºè­°ï¼šè«‹è«®è©¢é†«å¸«æˆ–è—¥å¸«äº†è§£è©³ç´°å»ºè­°ã€‚


## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### æ•´é«”è©•ä¼°

Oxytetracycline ç”¨æ–¼å¤–è€³ç‚çš„é æ¸¬å…·æœ‰è‰¯å¥½çš„è­‰æ“šæ”¯æŒï¼š

1. **è­‰æ“šç­‰ç´šä¸­ç­‰ (L2)**ï¼šæœ‰éš¨æ©Ÿå°ç…§è©¦é©—æ”¯æŒå…¶ç™‚æ•ˆ
2. **æ©Ÿè½‰åˆç†**ï¼šå»£æ•ˆæŠ—èŒä½œç”¨å¯æ¶µè“‹å¤–è€³ç‚å¸¸è¦‹ç—…åŸ
3. **å·²æœ‰ä¸Šå¸‚è£½åŠ‘**ï¼šå« oxytetracycline çš„è¤‡æ–¹è€³ç”¨è£½åŠ‘å·²åœ¨åœ‹éš›ä¸Šä½¿ç”¨
4. **å°ç£ç¾æ³**ï¼šåŸé©æ‡‰ç—‡å·²åŒ…å«è€³ç‚ï¼Œä½†å¤§éƒ¨åˆ†è—¥è­‰å·²è¨»éŠ·

### å»ºè­°è¡Œå‹•

- **è€ƒæ…®å¾©æ´»è—¥è­‰**ï¼šè‹¥æœ‰è‡¨åºŠéœ€æ±‚ï¼Œå¯è€ƒæ…®é‡æ–°ç”³è«‹å« oxytetracycline çš„è€³ç”¨è£½åŠ‘
- **è©•ä¼°æ›¿ä»£é¸é …**ï¼šç›®å‰ ciprofloxacin åŠ ofloxacin è€³æ»´åŠ‘ç‚ºä¸»æµæ²»ç™‚
- **å±€éƒ¨è£½åŠ‘å„ªå…ˆ**ï¼šé™ä½å…¨èº«æ€§å‰¯ä½œç”¨é¢¨éšª

### è‡¨åºŠå»ºè­°

å°æ–¼å¤–è€³ç‚æ²»ç™‚ï¼Œoxytetracycline å¯ä½œç‚ºæ›¿ä»£é¸é …ï¼Œç‰¹åˆ¥æ˜¯ï¼š
- å° fluoroquinolone éæ•çš„æ‚£è€…
- éœ€è¦åˆä½µæŠ—çœŸèŒæ²»ç™‚çš„æ··åˆæ„ŸæŸ“

---

*æœ¬å ±å‘Šç”± TxGNN é æ¸¬ç³»çµ±ç”Ÿæˆï¼Œåƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚*

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Amorolfine]({{ "/drugs/amorolfine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Trihexyphenidyl]({{ "/drugs/trihexyphenidyl/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Scopolamine]({{ "/drugs/scopolamine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Threonine]({{ "/drugs/threonine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Iodixanol]({{ "/drugs/iodixanol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Oxytetracyclineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/oxytetracycline/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_oxytetracycline,
  title = {Oxytetracyclineè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/oxytetracycline/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
